VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 137 filers reported holding VERVE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.34 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,978 | -29.3% | 300,000 | 0.0% | 0.17% | -1.7% |
| Q2 2023 | $5,625 | +30.0% | 300,000 | 0.0% | 0.17% | -32.3% |
| Q1 2023 | $4,326 | -25.5% | 300,000 | 0.0% | 0.26% | -20.7% |
| Q4 2022 | $5,805 | -100.0% | 300,000 | -25.0% | 0.32% | -44.7% |
| Q3 2022 | $13,740,000 | +124.8% | 400,000 | 0.0% | 0.59% | +79.8% |
| Q2 2022 | $6,112,000 | -33.0% | 400,000 | 0.0% | 0.33% | -14.7% |
| Q1 2022 | $9,128,000 | -38.1% | 400,000 | 0.0% | 0.38% | -4.5% |
| Q4 2021 | $14,748,000 | -21.6% | 400,000 | 0.0% | 0.40% | -5.0% |
| Q3 2021 | $18,800,000 | -37.6% | 400,000 | -20.0% | 0.42% | -31.1% |
| Q2 2021 | $30,125,000 | – | 500,000 | – | 0.61% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $26,636,807 | 17.30% |
| Alphabet Inc. | 10,549,086 | $139,880,880 | 8.98% |
| Casdin Capital, LLC | 2,954,710 | $39,179,455 | 4.34% |
| MPM BioImpact LLC | 857,940 | $11,376,284 | 3.04% |
| Saltoro Capital, LP | 66,500 | $881,790 | 0.79% |
| ARK Investment Management | 5,200,567 | $68,959,525 | 0.53% |
| Redmile Group, LLC | 809,777 | $10,737,643 | 0.51% |
| Ikarian Capital, LLC | 2,413 | $3,199,638 | 0.38% |
| Logos Global Management LP | 215,000 | $2,850,900 | 0.38% |
| Nikko Asset Management Americas, Inc. | 2,147,243 | $28,429,497 | 0.34% |